Pharmacogenetic testing is gaining acceptance by a growing number of health insurers. On Oct. 1, UnitedHealthcare (UHC) began coverage of genetic tests that help physicians identify the anti-depressant drugs most likely to benefit their patients. UHC’s policy also extends coverage to multi-gene testing for antipsychotic drugs. In writing about this decision, www.clinicalomics.com said, “UnitedHealthcare’s policy …
November 4, 2019 Intelligence: Late Breaking Lab News Read More »
